Recombinant Human AMR Protein，His

AMR (Antimicrobial Resistance) has emerged as a critical global health challenge, significantly impacting treatment options for bacterial infections. Research into recombinant proteins associated with AMR aims to understand the mechanisms of resistance and develop novel therapeutic strategies. Bacteria can acquire resistance through various means, including horizontal gene transfer and mutations, leading to the production of enzymes like beta-lactamases, which degrade antibiotics. The study of AMR recombinant proteins involves the genetic engineering of bacteria to produce these proteins in a controlled laboratory setting, allowing researchers to analyze their structure and function. This approach not only enhances the understanding of how these proteins confer resistance but also aids in the development of inhibitors that can combat resistant strains. The research encompasses various bacterial species, focusing on both Gram-positive and Gram-negative bacteria, to encompass a broad spectrum of AMR determinants. Furthermore, recombinant proteins can serve as potential candidates for novel vaccines or therapeutic agents, contributing to the ongoing battle against AMR by providing new avenues for treatment. The urgency of addressing AMR is underscored by increasing rates of infection, prolonged hospital stays, and higher healthcare costs, motivating interdisciplinary research efforts in microbiology, biochemistry, and pharmacology to effectively tackle this pressing public health issue.